The Choice of Treatment Methods and Efficacy of LABC (NCT06080620) | Clinical Trial Compass
RecruitingNot Applicable
The Choice of Treatment Methods and Efficacy of LABC
China50 participantsStarted 2023-10-08
Plain-language summary
The goal of this clinical trial is to compare the therapeutic effects of chemotherapy followed by surgery and surgery followed by chemotherapy in patients with locally advanced breast cancer（LABC). Patients with LABC will be randomly divided into two groups, each receiving chemotherapy followed by surgery or surgery followed by chemotherapy. The main comparison was between the disease-free survival (DFS) of two groups of patients, with the secondary study endpoint being overall survival (OS); Five year survival; Local recurrence or distant metastasis rate.
Who can participate
Age range18 Years – 70 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. 18-70 year old female
✓. Patients with locally advanced breast cancer (stage IIIb - IIIc) first diagnosed;
✓. Clinical diagnosis of breast cancer, or puncture pathology suggests breast cancer;
✓. After evaluation by experienced clinical physicians, the patient's tumor has the possibility of surgical resection. Specific evaluation indicators include ultrasound assessment of the tumor not surrounding the axillary vein;
✓. Accept treatment plans including surgery, radiotherapy, and chemotherapy;
✓. Volunteer to participate in clinical research and sign an informed consent form;
✓. Willing to undergo follow-up and complete quality of life (EQ-5D series scale and FACT-B scale) and postoperative psychological status (Anxiety/Depression Self Rating Scale) assessments;
Exclusion criteria
✕. Patients under 18 years old or over 70 years old;
✕. Those who have received breast cancer related surgery, radiotherapy or chemotherapy;
✕. Those who are not expected to receive surgery, radiotherapy or chemotherapy related to breast cancer
✕. Other serious diseases that may significantly affect clinical trial compliance, such as severe cardiopulmonary dysfunction, liver and kidney dysfunction, poorly controlled diabetes and mental illness.